Macrophage-based anti-cancer therapy: Modelling different modes of tumour targeting

Bulletin of Mathematical Biology

Volumn 69, Issue 5, 2007, Pages 1747-1776

  Webb, Steven D ^a,b   Owen, Markus R ^a   Byrne, Helen M ^a   Murdoch, Craig ^c   Lewis, Claire E ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bifurcation; Bystander effect; Cancer; Gene therapy; Hypoxia; Macrophage; Parameter continuation

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; ENZYME; PRODRUG;

ALGORITHM; APOPTOSIS; ARTICLE; BIOLOGICAL MODEL; CELL HYPOXIA; CELL SURVIVAL; COMPUTER SIMULATION; DRUG EFFECT; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; KINETICS; MACROPHAGE; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; TRANSPLANTATION;

ALGORITHMS; APOPTOSIS; CELL HYPOXIA; CELL SURVIVAL; COMPUTER SIMULATION; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYMES; GENE THERAPY; HUMANS; KINETICS; MACROPHAGES; MODELS, BIOLOGICAL; NEOPLASMS; PRODRUGS; TRANSFECTION;

EID: 34250712338     PISSN: 00928240     EISSN: 15229602     Source Type: Journal    
DOI: 10.1007/s11538-006-9189-2     Document Type: Article

References (49)

1. Adam, J.A., Bellomo, N., 1997. A Survey of Models for Tumor-Immune System Dynamics. Birkhäuser, Cambridge, MA.
2. Andreesen, R., Hennemann, B., Krause, S.W., 1998. Adoptive immunotherapy of cancer using monocyte-derived macrophages: Rationale, current status, and perspectives. J. Leukoc. Biol. 64, 419-426.
3. Bingle, L., Brown, N.J., Lewis, C.E., 2002. The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J. Pathol. 196, 254-265.
4. Breward, C.J.W., Byrne, H.M., Lewis, C.E., 2001. Modelling the interactions between tumour cells and a blood vessel in a microenvironment within a vascular tumour. Eur. J. Appl. Math. 12, 529-556.
5. Breward, C.J.W., Byrne, H.M., Lewis, C.E., 2003. A multiphase model describing vascular tumour growth. Bull. Math. Biol. 65, 609-640.
6. Brown, J.M., 1999. The hypoxic cell: A target for selective cancer therapy-Eighteenth Bruce F Cain Memorial Award lecture. Cancer Res. 59, 5863-5870.
7. Byrne, H.M., Cox, S.M., Kelly, C.E., 2004. Macrophage-tumour interactions in vivo. Discrete Contin. Dyn. Syst., Ser. B 4, 81-98.
8. Byrne, H.M., Alarcón, T., Owen, M.R., Webb, S.D., Maini, P.K., 2006. Modelling aspects of cancer dynamics: A review. Philos. Trans. R. Soc. A 364, 1563-1578.
9. Cersosimo, R.J., 2003. Tamoxifen for prevention of breast cancer. Ann. Pharmacother. 37, 268-273.
10. Crowther, M., Brown, N.J., Bishop, E.T., Lewis, C.E., 2001. Microenvironmental influence of macrophage regulation of angiogenesis in wounds and malignant tumours. J. Leukoc. Biol. 70, 478-490.
11. Dent, P., Grant, S., 2004. Irofulven: resurgence for alkylating therapy in cancer. Cancer Biol. Ther. 3, 1143-1144.
12. Doedel, E.J., Champneys, A.R., Fairgrieve, T.R., Kuznetsov, Y.A., Sandstede, B., Wang, X.J., 1997. AUTO 97: Continuation and bifurcation software for ordinary differential equations. Available from http://indy.cs.concordia.ca/ auto/main.html.
13. Drasdo, D., Hohme, S., 2003. Individual-based approaches to birth and death in avascular tumors. Math. Comput. Modelling 37, 1163-1175.
14. Freyer, J.P., Sutherland, R.M., 1983. Determination of apparent diffusion constants for metabolites in multicell tumour spheroids. Adv. Exp. Med. Biol. 159, 463-475.
15. Gatenby, R.A., 1995. The potential role of transformation-induced changes in tumor-host interface. Cancer Res. 55, 4151-4156.
16. Griffiths, L., Binley, K., Iqball, S., Kan, O., Maxwell, P., Ratcliffe, P., Lewis, C., Harris, A., Kingsman, S., Naylor, S., 2000. The macrophage-a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 7, 255-262.
17. Gunther, M., Waxman, D.J., Wagner, E., Ogris, M., 2006. Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy. Cancer Gene Ther. 13, 771-779.
18. Hibbs, J.B., Taintor, R.R., Vavrin, Z., Rachlin, E.M., 1988. Nitric-oxide-A cytotoxic activated macrophage effector molecule. Biochem. Biophys. Res. Commun. 157, 87-94.
19. Hlatky, L., Suchs, R.K., Alpen, E.L., 1988. Joint oxygen-glucose deprivation as the cause of necrosis in a tumour analogue. J. Cell. Physiol. 134, 167-178.
20. Kelly, P.M., Davison, R.S., Bliss, E., McGee, J.O., 1988. Macrophages in human breast disease: A quantitative immunohistochemical study. Br. J. Cancer 57, 174-177.
21. Kelly, C.E., Leek, R.D., Byrne, H.M., Cox, S.M., Harris, A.L., Lewis, C.E., 2002. Modelling macrophage infiltration into avascular tumours. J. Theor. Med. 4, 21-38.
22. Leek, R.D., 1999. The Role of Tumour Associated Macrophages in Breast Cancer Angiogenesis. PhD thesis, Oxford Brookes University, Oxford.
23. Leek, R.D., Harris, A.L., Lewis, C.E., 1994. Cytokine networks in solid human tumours: Regulation of angigenesis. J. Leukoc. Biol. 56, 423-435.
24. Leek, R.D., Lewis, C.E., Whitehouse, R., Greenall, M., Clarke, J., Harris, A.L., 1996. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56, 4625-4629.
25. Leek, R.D., Landers, R.J., Harris, A.L., Lewis, C.E., 1999. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer 79, 991-995.
26. Lewis, C.E., Murdoch, C., 2005. Macrophage responses to hypoxia: implications for tumor progession and anti-cancer therapies. Am. J. Pathol. 167, 627-635.
27. Mantzaris, N., Webb, S.D., Othmer, H.G., 2004. Mathematical modelling of tumour angiogenesis: A review. J. Math. Biol. 49, 111-187.
28. Maxwell, P.H., Dachs, G.U., Gleadle, J.M., Nicholls, L.G., Harris, A.L., Stratford, I.J., Hankinson, O., Pugh, C.W., Ratcliffe, P.J., 1997. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94, 8104-8109.
29. Murdoch, C., Giannoudis, A., Lewis, C.E., 2004. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104, 2224-2234.
30. Negus, R.P., Stamp, G.W., Hadley, J., Balkwill, F.R., 1997. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 150, 1723-1734.
31. Ohno, S., Ohno, Y., Suzuki, N., Kamei, T., Koike, K., Inagawa, H., Kohchi, C., Soma, G.I., Inoue, M., 2004. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res. 24, 3335-3342.
32. O'Shaughnessy, J.A., 2004. New perspectives with antimetabolites in the management of breast cancer. Clin. Breast Cancer 4, S99-S100.
33. Owen, M.R., Sherratt, J.A., 1997. Pattern formation and spatiotemporal irregularity in a model for macrophage-tumour interactions. J. Theor. Biol. 189, 63-80.
34. Owen, M.R., Sherratt, J.A., 1998. Modelling the macrophage invasion of tumours: Effects on growth and composition. IMA J. Math. Appl. Med. Biol. 15, 165-185.
35. Owen, M.R., Byrne, H.M., Lewis, C.E., 2004. Mathematical modelling of the use of macrophages as vehicles for drug-delivery to hypoxic tumour sites. J. Theor. Biol. 226, 377-391.
36. Perumpanani, A.J., Byrne, H.M., 1999. Extracellular matrix concentration exerts selection pressure on invasive cells. Eur. J. Cancer 35, 1274-1280.
37. Pollard, J.W., 2004. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71-78.
38. Ross, J.A., Auger, M.J., 2002. The biology of the macrophage. In: Burke, B., Lewis, C.E. (Eds.), The Macrophage, 2nd edition. Oxford University Press, Oxford, 1-72
39. Sica, A., Saccani, A., Bottazi, B., Polentarutti, N., Vecchi, A., van Damme, J., Mantovani, A., 2000. Autocrine production of IL-10 mediates defective IL-12 production and NF-κ B activation in tumor-associated macrophages. J. Immunol. 164, 762-767.
40. Sica, A., Sacccani, A., Mantovani, A., 2002. Tumor-associated macrophages: a molecular perspective. Int. Immunopharmacol. 2, 1045-1054.
41. Siegert, A., Denkert, C., Leclere, A., Hauptmann, S., 1999. Suppression of the reactive oxygen intermediates production of human macrophages by colorectal adenocarcinoma cell lines. Immunology 98, 551-556.
42. Sozzani, S., Luini, W., Molino, M., Jilek, P., Bottazzi, B., Cerletti, C., Matsushima, K., Mantovani, A., 1991. The signal transduction pathway involved in the migration induced by a monocyte chemotactic cytokine. J. Immunol. 147, 2215-2221.
43. Trinchieri, G., 1998. Interleukin-12: A cytokine at the interface of inflammation and immunity. Adv. Immunol. 70, 83-243.
44. Urban, J.L., Shepard, H.M., Rothstein, J.L., Sugarman, B.J., Schreiber, H., 1986. Tumor-necrosis-factor-A potent effector molecule for tumor-cell killing by activated macrophages. Proc. Nat. Acad. Sci. USA 83, 5233-5237.
45. Vaupel, P., Kelleher, D.K., Hockel, M., 2001. Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin. Oncol. 28, 29-35.
46. Ward, J.P., King, J.R., 1997. Mathematical modelling of avascular tumour growth. IMA J. Math. Appl. Med. Biol. 14, 39-69.
47. Ward, J.P., King, J.R., 1999a. Mathematical modelling of avascular tumour growth II: Modelling growth saturation. IMA J. Math. Appl. Med. Biol. 16, 171-211.
48. Ward, J.P., King, J.R., 1999b. Mathematical modelling of the effects of mitotic inhibitors on avascular tumour growth. J. Theor. Med. 1, 287-311.
49. Ward, J.P., King, J.R., 2003. Mathematical modelling of drug transport in tumour multicell spheroids and monolayer cultures. Math. Biosci. 181, 177-207.